ADAM17 and pancreatic neoplasm: Taken together, our data identified CUX1 as an important enhancer of KRAS-induced tumor development in pancreatic cancer, acting synergistically with oncogenic KRAS by inducing several upstream and downstream effectors such as ADAM17 and MOS.